All the sessions from Transform 2021 are available on-demand now. Watch now.

Crescendo Bioscience, developer of tests that take a closer look at autoimmune and inflammatory diseases affecting joints, has raised $5 million more in a second round of venture funding, bringing its total to $20 million, according to Dow Jones VentureWire. Based in South San Francisco, the company is backed by Kleiner Perkins Caufield & Byers and Mohr Davidow Ventures.

It will use its new money to prep for the launch of its first product. The company has not revealed much about the launch, but it has been working primarily on tests for arthritis.


VentureBeat's mission is to be a digital town square for technical decision-makers to gain knowledge about transformative technology and transact. Our site delivers essential information on data technologies and strategies to guide you as you lead your organizations. We invite you to become a member of our community, to access:
  • up-to-date information on the subjects of interest to you
  • our newsletters
  • gated thought-leader content and discounted access to our prized events, such as Transform 2021: Learn More
  • networking features, and more
Become a member